Opexa's Stem Cell Therapy For Diabetes Shows Progress
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company dedicated to the development of stem cell therapies for diabetes announced new preclinical data to support its autologous stem cell therapy program. Opexa completed confirmatory studies within its c-GMP facility showing that cells obtained from peripheral blood have the ability to differentiate into stem cells and ultimately into pancreatic-like cells.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment